Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
9538149
DOI
10.3892/ijo.12.5.1195
Knihovny.cz E-zdroje
- MeSH
- CD4-pozitivní T-lymfocyty imunologie MeSH
- CD8-pozitivní T-lymfocyty imunologie MeSH
- DNA vakcíny * MeSH
- genetická terapie metody MeSH
- interleukin-2 biosyntéza genetika MeSH
- lymfocytární deplece * MeSH
- myši inbrední BALB C MeSH
- myši MeSH
- nádorové buňky kultivované účinky záření MeSH
- plazmocytom imunologie patologie terapie MeSH
- protinádorové vakcíny * MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- DNA vakcíny * MeSH
- interleukin-2 MeSH
- protinádorové vakcíny * MeSH
The effect of irradiation on the therapeutic efficacy of IL-2 gene-modified plasmacytoma cells used as a vaccine in the immunotherapy of parental murine plasmacytoma X63-Ag8.653 was examined. Local administration of the IL-2-secreting plasmacytoma irradiated with a dose of 50 Gy inhibited i.p. plasmacytoma growth more effectively than the administration of non-irradiated, live cell vaccines. Whereas the vaccination with the live cell vaccine could substantially prolong the survival of the tumour-bearing mice but did not significantly induce tumour regressions, the irradiated vaccines could substantially increase the number of tumour-free animals. The irradiated vaccines produce higher amounts of IL-2 than the live cell vaccines both in vitro and in vivo. Depletion of CD4+ and CD8+ effector cells with monoclonal antibodies has significantly decreased the effect of the vaccination. It can be concluded that both, CD4+ and CD8+ T lymphocytes are required for effective IL-2 gene therapy of the X63-Ag8.653 plasmacytoma and that the higher effect of the irradiated vaccines is probably due to their higher IL-2 production.
Citace poskytuje Crossref.org